Pimecrolimus
Mechanism :
Pimecrolimus binds to the intracellular protein FKBP-12, inhibiting calcineurin, which blocks cytokine transcription and inhibits T-cell activation.
Indication :
- Atopic dermatitis: Second-line therapy for short-term and non-continuous long-term treatment of mild to moderate atopic dermatitis in immunocompetent patients 2 years and older.
- Off-label: Intertriginous and facial psoriasis; Oral lichen planus; Vitiligo.
Contraindications :
Hypersensitivity to pimecrolimus or any component of the formulation.
Dosing :
≥2 years:
Apply cream (1%) thin layer to affected area twice daily.
Adverse Effect :
Headache, fever, influenza, local burning, nasopharyngitis, bronchitis, folliculitis, acne vulgaris, impetigo, warts, hypersensitivity, sore throat, asthma.
Interaction :
CYP3A4 Inhibitors: May decrease the metabolism of Pimecrolimus.
Immunosuppressants: Pimecrolimus may enhance the adverse/toxic effect of Immunosuppressants.
Hepatic Dose :
No dose adjustment recommended.